While a small sam­pling, BIO's third di­ver­si­ty re­port pro­vides 'bench­mark' for da­ta-fo­cused in­dus­try to fur­ther an­a­lyze

The num­bers are some­what in and biotech di­ver­si­ty looks rel­a­tive­ly sim­i­lar to what it has been for years.

A 2021 sam­pling paints a very lim­it­ed pic­ture of the in­dus­try, with BIO’s third an­nu­al di­ver­si­ty re­port in­clud­ing on­ly 99 re­spon­dent com­pa­nies. Most ques­tions were not or could not be an­swered by every sin­gle or­ga­ni­za­tion, mean­ing many went unan­swered, such as in­sight on board-lev­el de­mo­graph­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER